nystatin-a1 has been researched along with Fever* in 4 studies
1 trial(s) available for nystatin-a1 and Fever
Article | Year |
---|---|
Antimicrobial therapy as a part of the decontamination procedures for patients with acute leukemia.
Topics: Acute Disease; Anti-Bacterial Agents; Bacitracin; Blood Cell Count; Blood Platelets; Disinfection; Drug Combinations; Fever; Germ-Free Life; Glucose; Hexetidine; Humans; Leukemia; Neomycin; Neutropenia; Nystatin; Patient Isolators; Pneumonia; Remission, Spontaneous; Respiratory Tract Infections; Sterilization; Thrombelastography; Time Factors; Xylose | 1973 |
3 other study(ies) available for nystatin-a1 and Fever
Article | Year |
---|---|
Strict protective isolation in allogenic bone marrow transplantation: effect on infectious complications, fever and graft versus host disease.
Complete microbial decontamination (laminar air flow room, sterile nursing and oral administration of cefamandole, gentamicin and nystatin) was carried out in 65 consecutive patients prior to allogeneic BMT for leukaemia (n = 58) or aplastic anaemia (n = 7). Very few microorganisms persisted during the post-transplant treatment period, and the gut became sterile in all except for Candida in 11 patients. Six uncomplicated septicaemias, all with persistent organisms simultaneously present in the mouth (Pseudomonas 3, Serratia 1, Candida 2) occurred during a total of 1,360 days with granulocyte counts less than 0.5 X 10(9)/l. Post-transplant fever occurred in 52 patients, exceeding 40 degrees C in 25. Guided by the surveillance cultures only 46% of 43 unexplained febrile reactions were treated with systemic antimicrobials. Significant acute graft versus host disease (AGVHD) occurred in 14 (27%) of 52 patients receiving standard prophylaxis and HLA-matched grafts; immunosuppressive treatment was needed in 8 cases (16%). Thus, the additional costs of total microbial decontamination appear partially regained by a decreased morbidity and a reduced need for antimicrobial and immunosuppressive treatment, although neither fever nor AGVHD could be prevented. Topics: Adolescent; Adult; Bone Marrow Transplantation; Cefamandole; Child; Child, Preschool; Environment, Controlled; Fever; Gentamicins; Graft vs Host Disease; Humans; Immunosuppression Therapy; Infection Control; Middle Aged; Nystatin; Patient Isolation; Transplantation, Homologous | 1987 |
Nystatin prophylaxis of fungal colonization and infection in granulocytopenic patients: correlation of colonization and clinical outcome.
Nystatin, one million units every four hours, was prospectively studied as a prophylactic antifungal agent in 164 neutropenic patients who were not initially colonized by fungi: 104 received nystatin and 60 served as controls. Fungal colonization occurred in 68/104 (65%) nystatin recipients and in 43/60 (71%) controls. However, nystatin significantly reduced multiple body site colonization and persistent oropharyngeal colonization. Despite these alterations in colonization profile, 16/104 (15%) nystatin recipients developed disseminated fungal infections, as compared to 5/60 (8%) control patients (0.5 greater than p greater than 0.1, N.S). Differences in the clinical course of colonized and non-colonized patients were observed. Eighteen of 111 (16%) colonized patients had afebrile clinical courses as compared to 16/53 (30%) non-colonized patients (p less than 0.05). Twenty-nine of 93 (31%) febrile episodes in colonized patients failed to respond to empiric antibiotic therapy as compared to 3/37 (8%) episodes in non-colonized patients (p less than 0.01). Disseminated fungal infections were diagnosed in 19/111 (17%) of colonized patients, as compared to 1/53 (2%) non-colonized patients (p less than 0.02). We conclude that colonized patients are more likely to develop febrile clinical courses, to fail to respond to empiric antibiotic therapy, and to develop disseminated fungal infection. Nystatin altered colonization patterns but did not prevent disseminated fungal infection. Topics: Adolescent; Adult; Aged; Agranulocytosis; Anti-Bacterial Agents; Drug Combinations; Female; Fever; Humans; Male; Middle Aged; Mycoses; Nystatin; Oropharynx; Prospective Studies; Random Allocation; Sulfamethoxazole; Trimethoprim; Trimethoprim, Sulfamethoxazole Drug Combination; Yeasts | 1985 |
[Complications in obstetric-gynecologic practice from antibiotic therapy].
Topics: Anti-Bacterial Agents; Cyanosis; Drug Eruptions; Drug Hypersensitivity; Edema; Episiotomy; Erythromycin Ethylsuccinate; Female; Fever; Hearing Disorders; Humans; Hysterectomy; Neomycin; Nystatin; Penicillins; Postoperative Care; Pregnancy; Pregnancy, Ectopic; Streptomycin; Tetracycline | 1968 |